WinstonWınston
Back
Stock

Viking Therapeutics

VKTX
Biotechnology · Healthcare
Also trades as: 0VQA.L GBP 0.25 (-5.37%)
Price
$24.40
-1.43 (-5.54%)
Market Cap
$3.10B
Exchange
NASDAQ
Winston Score
–
Winston looking sleepy
No score yet — nothing to grade.
This is a pre-revenue company — it has no sales yet, just exploration or development costs. There’s no operating business to grade on profitability, margins or cash flow, so the Winston Score stays blank until it starts booking revenue.
Track this stock — start free trial

Share count rising — dilution

+45.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 77.2M (2021) → 112.7M (2025)

§Winston Score History

The full picture

Viking Therapeutics is a clinical-stage biotechnology company focused on developing drugs to treat metabolic and endocrine diseases. Its lead drug candidates include VK2735, a weight-loss treatment targeting obesity, and VK2809, aimed at a liver disease called NASH (nonalcoholic steatohepatitis). The company does not yet sell any approved products — it is still running clinical trials to test whether its drugs are safe and effective.

Viking makes no revenue from product sales yet. It is funded primarily through stock offerings and partnerships, which is typical for early-stage biotech companies. Based in San Diego, California, Viking operates entirely in the United States at this stage. Its potential competitive edge lies in VK2735's strong early trial results in the fast-growing obesity drug market, where it competes against established treatments like Novo Nordisk's Ozempic and Eli Lilly's Zepbound. The biggest risk is that clinical trials could fail or regulatory approval could be denied, which would significantly impact the company's future.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

Reported EPS Growth

-89.7% YoY

Quarterly reporting periods ended:

30 Jun 2025: $-0.58

30 Jun 2026: $-1.10

Reported/statutory EPS, not adjusted or underlying earnings. One-off items can affect this figure. Provider rounding can affect the growth rate.

YoY Growth Rate

Reported EPS decreased year over year

R&D Spend

$345M/ year

↑ Rising (+239% vs prior year)

R&D investment increasing — building for the future

Insider Activity

10.6%ownership

↑ Rising

Insiders increasing their stake — aligned with shareholders

Cash Runway

~12 months

$502M cash & investments

Adequate runway but may need to raise capital within 2 years

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
N/A
—
Data not available
Profit after running costs
Operating Margin
N/A
—
Data not available
Return on the money invested
ROCE
-135.8%
Weak — -135.8% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
N/A
—
Data not available
Profit growth
EPS YoY
N/A
—
Data not available
How steady the profit is
EPS Consistency
1/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
—
Data not available
Spare cash per sale
FCF Margin
N/A
—
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.01
Conservative — low debt load (0.01)
Covers its interest
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
—
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial